Fusion Pharmaceuticals

Biotech & Life Sciences · Hamilton, Canada · Founded 2014 · IPO 2020

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing next-generation precision medicines for cancer treatment. The company operates in the biopharmaceutical market, focusing on creating innovative radiotherapeutics that target multiple tumor types. Fusion Pharmaceuticals serves cancer patients and healthcare providers, aiming to improve patient outcomes and quality of life. The business model revolves around research and development, leveraging proprietary linker technology to enhance the safety and efficacy of their treatments. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of their therapeutic products. The company is a spin-out from the Centre for Probe Development and Commercialization (CPDC), which provides it with a robust supply chain and extensive expertise in manufacturing. Fusion Pharmaceuticals is committed to pushing the boundaries of science to offer revolutionary cancer treatments. Keywords: precision medicines, radiotherapeutics, cancer treatment, proprietary linker technology, clinical-stage, biopharmaceutical, tumor targeting, patient outcomes, healthcare providers, CPDC.

Valuation $1–2.5B

Revenue $1–10M

Headcount <100

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Investors

19 investors on Fusion Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

FACIT (Fight Against Cancer Innovation Trust)

Series A 12 investors entered at this stage

Johnson & Johnson Development Corporation

Johnson & Johnson Innovation

TPG Biotech

Genesys Capital

HealthCap

Varian Medical Systems

Adams Street Partners

Seroba Life Sciences

OrbiMed

Pivotal Life Sciences

Rock Springs Capital

Perceptive Advisors

Series B+ 6 investors entered at this stage

Perceptive Advisors

Rock Springs Capital

Pivotal Life Sciences

McMaster University

OrbiMed

Centre For Probe Development And Commercialization

Global footprint

Where Fusion Pharmaceuticals has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States50%

🇨🇦 Canada42.3%

🇮🇳 India5.8%

🇪🇬 Egypt1.9%

4 countries shown

Web traffic by country

4.1K monthly visits
across markets

🇺🇸 United States61%

🇨🇦 Canada22%

🇮🇳 India17.1%

Top 3 markets shown

Talent graph

The shape of Fusion Pharmaceuticals's talent

Dealroom maps Fusion Pharmaceuticals's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 team members profilednamed & role-tagged by Dealroom

63 employeestotal headcount

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Fusion Pharmaceuticals's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Fusion Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Fusion Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Fusion Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles